Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.35 |
| ▸ | CA2 | P00918 | 5/20 | 0.35 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.35 |
| ▸ | CA7 | P43166 | 3/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2369612 | 0.94 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL2369616 | 0.94 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL14493144 | 0.92 | F2 (0.39) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL16298358 | 0.91 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL24927874 | 0.89 | F2 (0.36) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL15893686 | 0.85 | F2 (0.43) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL2615565 | 0.85 | F2 (0.43) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL2339827 | 0.83 | F2 (0.50) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL2339824 | 0.83 | F2 (0.50) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL13583119 | 0.83 | EPHX1 (0.41) | CA1CA2CA12CA14CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 688 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117352668-A | Preparation method of pyrophosphate secondary battery positive electrode material with high air stability | 深圳珈钠能源科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| WO-2004093821-A2 | TREATMENT OF ANTHRAX INFECTION USING INHIBITORS OF LETHAL FACTOR PROTEASE ACTIVITY | HAWAII BIOTECH, INC. (US) | 2004-11-04 | — | — | WO | claimed |
| US-20030232974-A1 | Guanidinylation, guanidinoglycosides, uses, and methods of assaying their activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-12-18 | — | — | US | claimed |
| US-20030055214-A1 | Guanidinylation reagents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-03-20 | — | — | US | claimed |
| EP-0983232-B1 | GUANIDINYLATION REAGENTS | UNIV CALIFORNIA (US) | 2002-11-13 | — | — | EP | claimed |
| US-6072075-A | Guanidinylation reagents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-06-06 | — | — | US | claimed |
| EP-0983232-A2 | GUANIDINYLATION REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998052917-A2 | GUANIDINYLATION REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-11-26 | — | — | WO | claimed |
| US-12636386-B2 | Compositions and methods for the treatment and imaging of cancer | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2026087442-A1 | AMINO-IMIDAZOLE ANTIBACTERIAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4724456-A1 | STEROL-BASED CATIONIC LIPIDS WITH AROMATIC HEAD GROUPS | Sanofi (FR) | 2026-04-15 | — | — | EP | disclosed |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-1182207-A2 | Non-covalent inhibitors of urokinase and blood vessel formation | CORVAS INTERNATIONAL, INC. (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-1040094-A1 | SUBSTITUTED CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS INC. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6072075-A | Guanidinylation reagents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0983232-A2 | GUANIDINYLATION REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1999033781-A1 | SUBSTITUTED CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
| WO-1998052917-A2 | GUANIDINYLATION REAGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232974-A1 | Guanidinylation, guanidinoglycosides, uses, and methods of assaying their activity | GMPS, GDA, RNGTT | F2 4314/4885PRSS1 949/4885PRSS2 1005/4885 |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | CCR1, CCRL2, CCR3 | F2 2252/4885PRSS1 3959/4885PRSS2 4487/4885 |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PHOSPHO1, LIPC, SDCBP | F2 4863/4885PRSS1 3497/4885PRSS2 4483/4885 |
| US-20260069549-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | SIN3A, PLIN3, MSR1 | F2 4766/4885PRSS1 4481/4885PRSS2 4623/4885 |
| US-12636386-B2 | Compositions and methods for the treatment and imaging of cancer | GBA1, GALC, CD47 | F2 2597/4885PRSS1 3241/4885PRSS2 4046/4885 |
| US-20030055214-A1 | Guanidinylation reagents | GDA, GMPS, GNMT | F2 4797/4885PRSS1 3126/4885PRSS2 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.